+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Synovial Sarcoma Drug"

Synovial Sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Synovial Sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Synovial Sarcoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Synovial Sarcoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Synovial Sarcoma - Pipeline Review, H2 2020 - Product Thumbnail Image

Synovial Sarcoma - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 419 Pages
  • Global
From
From
Synovial Sarcoma Market Report and Forecast 2024-2032 - Product Thumbnail Image

Synovial Sarcoma Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 180 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Synovial sarcoma is a rare type of cancer that affects the soft tissues of the body. It is most commonly found in the arms and legs, but can also occur in other parts of the body. Treatment for synovial sarcoma typically involves a combination of chemotherapy, radiation therapy, and surgery. Oncology drugs are used to treat cancer, and the market for synovial sarcoma drugs is a subset of the larger oncology drug market. The synovial sarcoma drug market is highly competitive, with a number of companies developing and marketing treatments for the disease. Companies in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. These companies are actively researching and developing new treatments for synovial sarcoma, as well as marketing existing treatments. Show Less Read more